Please enable Javascript
Uromigos Live 2023 - Bladder RT
Dosing, Cycle Considerations With EV/Pembrolizumab Combination
Thomas Powles, MBBS, MRCP, MD
Roundtable
|
November 28, 2023
The panel discussed optimal treatment cycles for enfortumab vedotin/pembrolizumab.
View More
Panel Shares Thoughts on EV-302 Study: Response Rate, Toxicities, Progression, and More
Thomas Powles, MBBS, MRCP, MD
Roundtable
|
November 28, 2023
The panel shared their thoughts on the EV-302 study.
View More
Frontline Bladder Cancer Updates From ESMO 2023 and How They Impact the Field
Thomas Powles, MBBS, MRCP, MD
Roundtable
|
November 28, 2023
The panel kicked off with conversations about data released at ESMO, including EV-302 and CheckMate 901.
View More
Panel Shares Predictions for What’s to Come in Advanced Urothelial Carcinoma
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel shares their hopes for the future of bladder cancer treatment.
View More
Panelists Share Best Practices, Strategies for Community Oncologists Managing Patients on EV/Pembro
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel shares tips for community oncologists who may not be familiar with treating patients with EV/pembro.
View More
Bladder Panel Talks Treatment Sequencing and Decisions in Different Patient Cases
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel shares treatment sequencing decisions based on a few patient scenarios.
View More
Combination Antibody-Drug Conjugate Strategy and the Future of Bladder Treatment
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel discussed the double antibody-drug conjugate trial that assessed sacituzumab govitecan plus EV.
View More
Reactions to Phase 3 THOR Study: Primary End Point Not Met
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel shares lessons learned from the phase THOR study.
View More
Bladder Panel Offers Insights on CheckMate 901 Study and Optimal Duration of Immunotherapy Treatment
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel discusses the CheckMate 901 study results.
View More
EV-302 Results and How They Compare to the JAVELIN Paradigm
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel discussed how the EV-302 data compare to the previous JAVELIN paradigm.
View More
Bladder Panel Reacts to EV-302 Data Presented at ESMO 2023
Peter O'Donnell, MD
Roundtable
|
November 17, 2023
The panel discusses the "buzz" around the EV-302 study.
View More
Panel Discusses Unmet Needs in Advanced Urothelial Carcinoma
Peter O'Donnell, MD
Roundtable
|
November 13, 2023
The panel discussed continued unmet needs and challenges for patients with urothelial cancer.
View More
Advertisement
Advertisement